Oxyglobin

About HbO2 Therapeutics

HbO2 Therapeutics is a private, commercial-stage biotech focused on oxygen-carrying therapeutics. Its core asset, Hemopure, is an approved human HBOC in select markets and is being developed for new applications in organ transplantation and severe anemia where blood transfusion is not an option. The company leverages over 25 years of R&D, a substantial preclinical and clinical data package, and an approved veterinary product to fund and de-risk its human therapeutic development.

Therapeutic Areas